Clinical bottom line
Biologic therapies targeting IL-17 pathways represent an important advance in managing moderate-to-severe inflammatory diseases such as psoriasis and certain forms of nasal polyposis. However, allergic reactions to these agents, including infusion or injection site reactions, hypersensitivity, and rare anaphylaxis, require careful diagnosis and management. Current evidence supports vigilant monitoring during initiation and ongoing treatment, with protocols for prompt recognition and treatment of allergic events. While IL-17 inhibitors generally have favorable safety profiles, clinicians should remain alert to potential allergic adverse effects, especially in patients with prior biologic hypersensitivity or multiple atopic comorbidities.
What the evidence shows
IL-17 pathway inhibitors, including secukinumab, ixekizumab, and brodalumab, have demonstrated efficacy in moderate-to-severe plaque psoriasis and eosinophilic nasal polyposis by modulating key inflammatory cytokines (Campa et al., 2015; Molinelli et al., 2018). These agents reduce disease activity by blocking IL-17A or its receptor, disrupting downstream inflammatory cascades.
Allergic reactions to IL-17 biologics are relatively uncommon but clinically significant. Strober et al. (2017) describe infusion and injection site reactions as the most frequent allergic manifestations, typically mild to moderate, including erythema, pruritus, and swelling. Rarely, systemic hypersensitivity reactions and anaphylaxis have been reported, necessitating immediate intervention.
Diagnosis of allergic reactions relies on clinical assessment, temporal association with drug administration, and exclusion of other causes. Skin testing and in vitro assays have limited validation for IL-17 inhibitors but may assist in select cases (Strober et al., 2017). Desensitization protocols remain largely unestablished for IL-17 agents, contrasting with more developed approaches for other biologics.
Management strategies emphasize prevention through patient education and premedication in high-risk individuals. Upon reaction occurrence, treatment includes antihistamines, corticosteroids, and epinephrine for anaphylaxis. Temporary or permanent discontinuation of the offending biologic may be necessary depending on reaction severity (Universidad Autónoma de Aguascalientes et al., 2025).
Notably, the IL-17 pathway’s role in host defense raises theoretical concerns about infection risk, but allergic reactions are mechanistically distinct and require separate clinical vigilance (Campa et al., 2015).
Caveats and uncertainty
The evidence base on allergic reactions to IL-17 biologics is limited by relatively small patient cohorts and short-term follow-up in clinical trials. Post-marketing surveillance data remain sparse, and real-world incidence rates of hypersensitivity reactions are not well defined. Additionally, diagnostic tools such as skin testing for IL-17 inhibitors lack standardization and validation, limiting their routine clinical utility.
There is also uncertainty regarding cross-reactivity among different IL-17 inhibitors and between IL-17 and other biologic classes, complicating management decisions in patients with prior biologic allergies. The absence of established desensitization protocols for IL-17 agents further constrains options for patients requiring continued therapy despite allergic reactions.
Finally, most data derive from psoriasis populations; extrapolation to other indications such as eosinophilic nasal polyposis warrants caution given potential differences in immune milieu and comorbidities (Elwany et al., 2026).
How this may change practice
Clinicians prescribing IL-17 pathway biologics should incorporate allergy risk assessment into baseline evaluations, including history of prior biologic reactions and atopic disease. Patient counseling on recognizing early allergic symptoms and prompt reporting is essential.
During IL-17 biologic initiation, observation periods and readiness for emergency management of hypersensitivity reactions should be standard. In cases of mild allergic reactions, symptomatic treatment and continued therapy with close monitoring may be appropriate. Severe or systemic reactions necessitate discontinuation and referral to allergy specialists for further evaluation.
Development and validation of diagnostic assays and desensitization protocols for IL-17 inhibitors would enhance clinical management but currently remain unmet needs. Multidisciplinary collaboration between dermatology, allergy, and immunology specialists is recommended to optimize care.
Overall, awareness of allergic reactions to IL-17 biologics and structured management approaches can improve patient safety and therapeutic outcomes in inflammatory diseases.